Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S.

Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809. doi: 10.1177/1756286419837809. eCollection 2019.

2.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

PMID:
30635477
3.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

4.

Coding in Multiple Sclerosis and Other Demyelinating Diseases.

Korb PJ, Miravalle A.

Continuum (Minneap Minn). 2016 Jun;22(3):951-9. doi: 10.1212/CON.0000000000000322. Review. No abstract available.

PMID:
27261692
5.

Remyelination Therapy in Multiple Sclerosis.

Harlow DE, Honce JM, Miravalle AA.

Front Neurol. 2015 Dec 10;6:257. doi: 10.3389/fneur.2015.00257. eCollection 2015. Review.

6.

Immune-Mediated Neurological Disorders.

Liewluck T, Miravalle A.

Curr Neurol Neurosci Rep. 2015 Sep;15(9):61. doi: 10.1007/s11910-015-0581-x. Review.

PMID:
26202897
7.

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K.

Mult Scler Relat Disord. 2014 Mar;3(2):227-36. doi: 10.1016/j.msard.2013.09.004. Epub 2013 Nov 2.

PMID:
25878010
8.

Neurologic complications of vaccinations.

Miravalle AA, Schreiner T.

Handb Clin Neurol. 2014;121:1549-57. doi: 10.1016/B978-0-7020-4088-7.00103-6. Review.

PMID:
24365435
9.

Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.

Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.

Am J Manag Care. 2013 Apr;19(4):278-85.

10.

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.

J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. Review.

PMID:
22710964
11.

Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.

Schreiner TL, Miravalle A.

J Cent Nerv Syst Dis. 2012 Jan 3;4:1-14. doi: 10.4137/JCNSD.S5128. Print 2012.

12.

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.

Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP.

Mult Scler. 2012 Mar;18(3):377-8. doi: 10.1177/1352458511418631. Epub 2011 Aug 9. No abstract available.

PMID:
21828201
13.

Guidelines and best practices for appropriate use of dalfampridine in managed care populations.

Miravalle AA.

Am J Manag Care. 2011 May;17 Suppl 5 Improving:S154-60. Review.

14.

Recent insights into the mechanism of action of glatiramer acetate.

Kala M, Miravalle A, Vollmer T.

J Neuroimmunol. 2011 Jun;235(1-2):9-17. doi: 10.1016/j.jneuroim.2011.01.009. Epub 2011 Mar 13. Review.

PMID:
21402415
15.

Therapeutic options in multiple sclerosis: five new things.

Miravalle A, Corboy JR.

Neurology. 2010 Nov 2;75(18 Suppl 1):S22-7. doi: 10.1212/WNL.0b013e3181fb3676. Review. No abstract available.

PMID:
21041767
16.

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.

Miravalle A, Jensen R, Kinkel RP.

Arch Neurol. 2011 Feb;68(2):186-91. doi: 10.1001/archneurol.2010.257. Epub 2010 Oct 11.

PMID:
20937940
17.

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.

Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T.

Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. No abstract available.

PMID:
20818795
18.

Neurological complications following vaccinations.

Miravalle A, Biller J, Schnitzler E, Bonwit A.

Neurol Res. 2010 Apr;32(3):285-92. doi: 10.1179/016164110X12645013515214. Review.

PMID:
20406607
19.

Recent advances in the treatment of multiple sclerosis.

Bennett JL, Miravalle AA.

J Exp Pharmacol. 2010 Nov 2;2:155-61. doi: 10.2147/JEP.S7822. eCollection 2010. Review.

20.

Emerging therapies for treatment of multiple sclerosis.

Corboy JR, Miravalle AA.

J Inflamm Res. 2010;3:53-9. Epub 2010 Jul 23.

21.

Acute disseminated encephalomyelitis: yellow fever vaccination.

Miravalle A, Biller J, Silva E, Conneely M, O'Keefe P.

Arq Neuropsiquiatr. 2009 Sep;67(3A):710-1. No abstract available.

22.

Encephalitis complicating smallpox vaccination.

Miravalle A, Roos KL.

Arch Neurol. 2003 Jul;60(7):925-8. Review.

PMID:
12873847

Supplemental Content

Loading ...
Support Center